Physician profile
Mary E Dougherty
NPI 1215909064
$3,159.03
in general payments reported to CMS, 2019-2025
11 companies · $657 in 2025
The $657 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $78.85 · 2021: $43.79 · 2022: $26.28 · 2023: $222 · 2024: $1,786 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741 · Travel and Lodging: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,740.68 |
| Travel and Lodging | $924.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,568.05 | 2021-2025 | Tryptyr, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $377.65 | 2020-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $349.91 | 2023-2025 | Miebo, Xiidra |
| Sight Sciences, INC. | $148.99 | 2024 | Omni Surgical System |
| Dompe US, INC. | $124.98 | 2025 | Oxervate |
| Shire North American Group INC | $124.58 | 2019 | |
| Abbvie INC. | $124.58 | 2019 | |
| Rxsight INC | $114.02 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Astellas Pharma US INC | $111.56 | 2024 | Izervay |
| Visioneering Technologies, INC. | $95.67 | 2019 | |
| Coopervision INC. | $19.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Dougherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.